#USA #San Diego #Crenessity #Neurocrine Biosciences #Congenital Adrenal Hyperplasia

Introduction

Neurocrine Biosciences Inc. recently unveiled new expert recommendations that provide guidance for healthcare providers on how to adjust glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) once they begin treatment with CRENESSITY® (crinecerfont). This exciting development comes in light of their recent publication in the esteemed Journal of Clinical Endocrinology and Metabolism, marking a vital step towards standardizing care for those affected by this rare genetic condition.

Importance of the Recommendations

Classic CAH arises from a deficiency in adrenal steroid hormone production, resulting in a condition that necessitates careful hormone management. Patients traditionally manage their condition through hormone replacement therapies, often involving higher doses of glucocorticoids than necessary. These high doses can lead to serious side effects, which is why the latest recommendations aim to steer clinicians towards a safer and more effective approach using CRENESSITY.

CRENESSITY's Role

CRENESSITY, a potent oral antagonist, helps by reducing the production of excess adrenal androgens, thus allowing patients to transition towards a more physiologic glucocorticoid dosing regime. This agent not only controls androgen levels but also addresses the accompanying risks associated with prolonged high glucocorticoid exposure, such as cardiovascular issues and metabolic complications.

Expert Recommendations Overview

The guidelines tailored for both pediatric patients (ages four to 17) and adult patients (18 years and older) represent a groundbreaking effort to refine treatment strategies. These recommendations include structured algorithms designed to help healthcare providers systematically decrease glucocorticoid doses, providing separate pathways due to the differing needs of children and adults:

1. For Pediatric Patients:
- Focus on achieving normal growth and bone development while minimizing complications associated with excess glucocorticoid therapy.
- Recommends gradual reductions of glucocorticoids to the upper range of physiological levels, while monitoring androgen levels closely.

2. For Adult Patients:
- Concentrates on the reduction of glucocorticoid-related side effects while controlling androgen levels.
- Suggests adjusting GC doses to achieve physiological ranges, pacing the reductions in accordance with the patient's current dosage to monitor for withdrawal symptoms effectively.

Clinical Implications

Dr. Sanjay Keswani, the Chief Medical Officer of Neurocrine Biosciences, emphasized the transformative potential of CRENESSITY in the management of CAH, noting how this new approach allows for more tailored and effective treatment strategies. The algorithms recognize that achieving a balance between disease management and quality of life is crucial, particularly in pediatric populations where growth and development are in progress.

Dr. Mimi Kim, from the Keck School of Medicine, highlighted the importance of these recommendations as they guide physicians through a careful balance between suppressing androgen production while supporting normal adolescent development. Similarly, Dr. Oksana Hamidi pointed out that such a structured approach not only helps in managing glucocorticoid exposure but also enhances patient outcomes in everyday clinical settings.

Conclusion

The newly introduced expert recommendations from Neurocrine Biosciences signify a noteworthy advancement in the treatment of classic congenital adrenal hyperplasia, aiming to improve the quality of care for both pediatric and adult patients. The protocols provided serve to empower healthcare providers with a clear framework for adjusting glucocorticoid dosing, minimizing unnecessary complications, and ultimately enhancing the overall treatment experience.

For more information and access to these essential guidelines, healthcare professionals can review the published articles in the Journal of Clinical Endocrinology and Metabolism.